SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049065
Filing Date
2024-04-26
Accepted
2024-04-26 16:00:50
Documents
5
Period of Report
2024-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A glue-def14a-2024_v2.htm DEF 14A 644839
2 GRAPHIC img48471903_0.jpg GRAPHIC 1302380
3 GRAPHIC img48471903_1.jpg GRAPHIC 1302380
4 GRAPHIC img48471903_2.jpg GRAPHIC 2461738
5 GRAPHIC img48471903_3.jpg GRAPHIC 332549
  Complete submission text file 0000950170-24-049065.txt   7941867
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40522 | Film No.: 24883362
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)